Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Slides:

Advertisements

Similar presentations

Agenda Introduction Classes of recommendations Level of evidence

Advertisements

Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

The Latest Device Therapy in W. Herts Dr Philip Moore.

Subgroup Placebo n/N (%) Serelaxin n/N (%)Favours placeboFavours serelaxin Odds ratio Estimate (95%CI) Interaction P value Total population150/580 (25.9)156/581.

To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.

IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.

Date of download: 6/26/2016 From: Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter- Defibrillator Versus.

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Mariell.

Fig ACCF/AHA Guideline for the management of heart failure

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation Ratika Parkash, MD, MSc, François Philippon,

Myocarditis in Clinical Practice

Developed in Collaboration With The American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,

Figure 8 Implanted devices for the management of heart failure

Diabetes Mellitus and Heart Failure

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

Clyde W. Yancy et al. JACC 2017;70:

Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

Figure 1 Energy supply–demand matching in health and heart failure

Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)

The American Association for Thoracic Surgery 2016 Ethics Forum: Cost-effectiveness and the ethics of left ventricular assist device therapy John W.C.

Step Care Therapy for Hypertension in Diabetic Patients

Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,

David D. Berg et al. JACC 2018;71:

Sexual Activity and Chronic Heart Failure

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Fig. 2. Evidence-based medication prescriptions

Nat. Rev. Cardiol. doi: /nrcardio

Volume 80, Issue 9, Pages (November 2011)

Ethnic and racial disparities in cardiac resynchronization therapy

Masashi Maeda et al. Heart Asia 2013;5:7-14

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Volume 15, Issue 1, Pages (January 2018)

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Rami Doukky et al. JCHF 2016;4:24-35

Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.

Relationship between the change in left ventricular ejection fraction (ΔLVEF) and change in left ventricular diastolic dimension (ΔLVDd) at 4 years at.

Figure 1 Diagnostic algorithm for cardiac transthyretin amyloidosis

Trends in LVAD implantation rates among the Medicare population from 2004 to Trends in LVAD implantation rates among the Medicare population from.

Figure 1 Patient selection

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Results of comparisons of treatments in the network.

(A) The ECG of a middle aged woman who was otherwise healthy but suffered a ventricular fibrillation cardiac arrest while receiving 20 mg daily of thioridazine.

Effect of sacubitril/valsartan on the rate of heart failure (HF) hospitalisations as a time to first event analysis and as a recurrent event analysis of.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

β-Blocker Use for the Stages of Heart Failure

The QT interval responses to different pacing rates in a patient in group I. The pacing rate was decreased from 110 to 50 beats/min and the QT interval.

Apical four chamber view in a patient with a bioprosthetic mitral valve and spontaneous echo contrast seen in the left ventricle. Apical four chamber view.

Cardiac MRI during the acute phase of the illness.

Kernel density plots of propensity score distributions in the included and excluded populations. Kernel density plots of propensity score distributions.

Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Treatment algorithm for DCM/PPCM, HCM and RCM during pregnancy and after delivery. Treatment algorithm for DCM/PPCM, HCM and RCM during pregnancy and after.

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Comparison of heart failure admissions rates per annum (recorded hospital admissions/ population at risk) in western developed countries 1978 to.

Survival free of atrial fibrillation after implantation of an implantable cardioverter defibrillator in our series (151 patients): overall population (solid.

Presentation transcript:

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Progressive therapies should be added in a stepwise fashion. Where two or more options exist on a step the most appropriate therapy for the patient based on concomitant medication or the presence of other patient factors should be made. NYHA, New York Heart Association; ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme inhibitor; ICD, implantable cardioverter defibrillator; CRT-P, cardiac resynchronisation therapy-pacemaker; CRT-D, cardiac resynchronisation therapy-defibrillator; LVAD, left ventricular assist device. Pardeep S Jhund, and John J V McMurray Heart 2016;102:1342-1347 Copyright © BMJ Publishing Group Ltd & British Cardiovascular Society. All rights reserved.